We focus on corneal transplantations, ocular surface reconstruction, corneal wound healing , corneal neovascularization (NV), corneal imaging, and corneal epithelial stem cells. The recent achievements are the discovery of novel treatment of corneal neovascularization with early injection of anti-VEGF monoclonal antibody ( bevacizumab ) for corneal pathologies with corneal NV and using in vivo confocal microscopy to detect corneal wound healing after corneal epithelial defect.
We focus on the pathogenesis of proliferative diabetic retinopathy (PDR) and treatments, including treatment modalities to accelerate clear-up of vitreous hemorrhage after vitrectomy, analyses of risk factors and exploration of therapeutic methods for recurrent vitreous hemorrhage after diabetic vitrectomy, and investigation of factors and cytokines involving in the pathogenesis of PDR.
We focus on pathogenesis of thyroid eye disease (TED) and development of new therapeutic modalities. We study the role of cytokines, autoantigens, COX-2 and PPAR-r in the pathogenesis of TED. We also cultivate orbital fat fibroblast and extraocular muscle to further investigate the mechanism of orbital fat proliferation and enlargement of extraocular muscle in TED.
We focus on myopia and amblyopia in preschool children. We have been engaging in the research of the prevalence of myopia among school children in Taiwan for more than 25 years. In addition, hereditary and/or environmental factors causing myopia are also to be analyzed. We actively participate in the nation-wide vision-screening program by using NTU random-dot stereogram and vision chart for kindergarten teachers to screen the small kids for strabismus and/or amblyopia.